Year-end report January – December 2020
The period in summary
January 1 – December 31, 2020
· Our marketing authorization application for Strangvac was submitted to the European Medicines Agency, EMA, at the end of February 2020. After having received the Day 120 questions from EMA we have strengthened the dossier. We are on track and are planning for a positive opinion from EMA during the second quarter 2021. · On June 16, a directed share issue of approximately 6.5 million shares was carried out, raising gross proceeds of approximately SEK 147 million. · We focus on the preparations for the launch of Strangvac,